formulação sólida oral do fármaco antituberculoso composto e método de preparo do mesmo

abstract provided is an oral solid preparation of a compound anti-tubercular drug, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. the compound oral solid preparation is a coated tablet with coated core or a coated three-layer tablet, wherein the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: MAOJIAN GU, QILAN ZHENG, LINTAO JIANG, LAN ZHENG, NING LI, MIN WANG, CHAO XU, GUIXIAN CHEN
Format: Patent
Sprache:por
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:abstract provided is an oral solid preparation of a compound anti-tubercular drug, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. the compound oral solid preparation is a coated tablet with coated core or a coated three-layer tablet, wherein the two active ingredients rifampicin and isoniazid do not contact directly. the compound oral solid preparation not only improves the stability of the compound preparation, but also improves the bioavailability of rifampicin. fig.1 a coated tablet with coated core --- tradução do resumo resumo patente de invenção: "formulação sólida oral do fármaco antituberculoso composto e método de preparo do mesmo". é fornecida uma preparação sólida oral de um fármaco antituberculoso composto, em que os ingredientes ativos são rifampicina, isoniazida, pirazinamida e cloridrato de etambutol. a preparação sólida oral composta é uma drágea revestida com núcleo revestido ou uma drágea de três camadas revestida, em que os dois ingredientes ativos rifampicina e isoniazida não entram em contato direto. a preparação sólida oral composta não apenas melhora a estabilidade da preparação de composto, como também melhora a biodisponibilidade de rifampicina. Provided is an oral solid preparation of a compound anti-tubercular drug, wherein the active ingredients are rifampicin, isoniazid, pyrazinamide and ethambutol hydrochloride. The compound oral solid preparation is a coated tablet with coated core or a coated three-layer tablet, wherein the two active ingredients rifampicin and isoniazid do not come to contact with each other directly. The compound oral solid preparation not only improves the stability of the compound preparation, but also improves the bioavailability of rifampicin.